Literature DB >> 16886606

The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression.

Kenneth A Iczkowski1, A Levi Omara-Opyene, Girish V Shah.   

Abstract

BACKGROUND: Prostate cancer (PC) consistently overexpresses variant the (v) isoform of the cell adhesion protein CD44, and loses expression of the standard (s) isoform.
MATERIALS AND METHODS: We re-expressed CD44 full-length (exons 1-20) or standard (exons 1-5 + 16-20) or enforced stable RNAi against CD44v, and the examined functional effects on PC. The effect of stable knockout of calcitonin, a paracrine factor, or its receptor, on CD44 was assessed.
RESULTS: Re-expression of full-length CD44 or CD44s increased the total CD44 mRNA and CD44s protein while suppressing CD44v. These approaches, and RNAi to CD44v, decreased invasion. In adhesion assays, benign prostate cells bound mainly to hyaluronan, whereas PC lost affinity for hyaluronan but bound more strongly to fibronectin. Re-expressing CD44s restored predominant hyaluronan binding. Knockout of the calcitonin receptor in PC-3 derived cells caused marked loss of CD44v expression and reversion to CD44s expression.
CONCLUSION: Calcitonin influenced PC's balance between CD44s and CD44v. CD44v controlled invasiveness, altered ligand binding, and provides a target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886606

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.

Authors:  Kui Yang; Yaqiong Tang; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

2.  Cell adhesion molecule CD44: its functional roles in prostate cancer.

Authors:  Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-09-12       Impact factor: 4.060

Review 3.  Rheostatic signaling by CD44 and hyaluronan.

Authors:  Ellen Puré; Richard K Assoian
Journal:  Cell Signal       Date:  2009-01-13       Impact factor: 4.315

4.  Silibinin suppresses CD44 expression in prostate cancer cells.

Authors:  Alina M Handorean; Kui Yang; Eric W Robbins; Thomas W Flaig; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

Review 5.  Hyaluronan: a simple polysaccharide with diverse biological functions.

Authors:  Kevin T Dicker; Lisa A Gurski; Swati Pradhan-Bhatt; Robert L Witt; Mary C Farach-Carson; Xinqiao Jia
Journal:  Acta Biomater       Date:  2013-12-18       Impact factor: 8.947

6.  MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro.

Authors:  Kui Yang; Alina M Handorean; Kenneth A Iczkowski
Journal:  Int J Clin Exp Pathol       Date:  2008-11-26

7.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

8.  MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.

Authors:  Eric W Robbins; Emily A Travanty; Kui Yang; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2008-09-15       Impact factor: 4.430

9.  Discovery of novel alternatively spliced C. elegans transcripts by computational analysis of SAGE data.

Authors:  Peter Ruzanov; Steven J Jones; Donald L Riddle
Journal:  BMC Genomics       Date:  2007-11-30       Impact factor: 3.969

10.  CD44-mediated activation of α5β1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices.

Authors:  Suzanne McFarlane; Cheryl McFarlane; Nicola Montgomery; Ashleigh Hill; David J J Waugh
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.